Last reviewed · How we verify
Lysozyme hydrochloride — Competitive Intelligence Brief
marketed
Antimicrobial enzyme
Peptidoglycan (bacterial cell wall component)
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Lysozyme hydrochloride (Lysozyme hydrochloride) — Eisai Co., Ltd.. Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lysozyme hydrochloride TARGET | Lysozyme hydrochloride | Eisai Co., Ltd. | marketed | Antimicrobial enzyme | Peptidoglycan (bacterial cell wall component) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antimicrobial enzyme class)
- Eisai Co., Ltd. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lysozyme hydrochloride CI watch — RSS
- Lysozyme hydrochloride CI watch — Atom
- Lysozyme hydrochloride CI watch — JSON
- Lysozyme hydrochloride alone — RSS
- Whole Antimicrobial enzyme class — RSS
Cite this brief
Drug Landscape (2026). Lysozyme hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/lysozyme-hydrochloride. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing